ClinicaliQ Trial Snapshot
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Active Not Recruiting • Phase III • Neurology • NCT05156281.
- Remibrutinib and teriflunomide showed similar effectiveness and safety for treating relapsing multiple sclerosis.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS) Conditions: Relapsing Multiple Sclerosis Interventions: Remibrutinib, Teriflunomide Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 1007 participants